
    
      A multi-centre, randomised, double-blind, placebo-controlled, parallel-group, multiple dose
      study to evaluate the tolerability of four intradermal doses of TM-HDM in subjects with
      controlled asthma and HDM-induced rhinoconjunctivitis.
    
  